

Mutant lamins cause nuclear envelope rupture and DNA damage in skeletal muscle cells

Ashley J. Earle^{1,*}, Tyler J. Kirby^{1,*}, Gregory R. Fedorchak^{1,*}, Philipp Isermann¹, Jineet Patel¹, Sushruta Iruvanti¹, Steven A. Moore², Gisèle Bonne³, Lori L. Wallrath⁴, and Jan Lammerding^{1,#}

¹ Meinig School of Biomedical Engineering & Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA

² Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA USA

³ Sorbonne Université, Inserm UMRS 974, Center of Research in Myology, Association Institute of Myology, Paris, France

⁴ Department of Biochemistry, Carver College of Medicine, University of Iowa, Iowa City, IA, USA

* These authors contributed equally

Correspondence should be addressed to:

Jan Lammerding
Weill Hall, Room 235, Ithaca, NY 14853, USA
jan.lammerding@cornell.edu

ABSTRACT

Mutations in the *LMNA* gene, which encodes the nuclear envelope (NE) proteins lamins A/C, cause Emery-Dreifuss muscular dystrophy, congenital muscular dystrophy, and other diseases collectively known as laminopathies. The mechanisms responsible for these diseases remain incompletely understood. Using three mouse models of muscle laminopathies and muscle biopsies from individuals with *LMNA*-related muscular dystrophy, we found that *Lmna* mutations reduced nuclear stability and caused transient rupture of the NE in skeletal muscle cells, resulting in DNA damage, DNA damage response activation, and reduced cell viability. NE and DNA damage resulted from nuclear migration during skeletal muscle maturation and correlated with disease severity in the mouse models. Reducing cytoskeletal forces on the myonuclei prevented NE damage and rescued myofiber function and viability in *Lmna* mutant myofibers, indicating that myofiber dysfunction is the result of mechanically induced NE damage. Taken together, these findings implicate mechanically induced DNA damage as a pathogenic contributor for *LMNA* skeletal muscle diseases.

INTRODUCTION

Lamins are the major components of the nuclear lamina, which lines the inner nuclear membrane. Lamins A/C provide structural support to the nucleus, connect the nucleus to the cytoskeleton, and participate in transcriptional regulation, genome organization, and DNA damage repair^{1, 2}. *LMNA* mutations cause autosomal dominant Emery-Dreifuss muscular dystrophy (AD-EDMD), characterized by skeletal muscle wasting, joint contractures, and cardiomyopathy, congenital muscular dystrophy (*LMNA*-CMD), a particularly severe form of muscular dystrophy, and other muscle diseases^{3, 4}. It remains unclear how the ubiquitously expressed mutant lamins cause muscle-specific defects. One explanation is that *LMNA* mutations result in structurally impaired nuclei that become damaged in mechanically active tissues². This hypothesis is supported by findings of decreased nuclear stiffness in fibroblasts expressing *LMNA* mutations linked to striated muscle laminopathies, impaired assembly of mutant lamins, and reports of NE damage in muscle cells of individuals with AD-EDMD and *LMNA*-related dilated cardiomyopathies^{1, 5, 6}. It remains unclear, however, whether the NE damage is a cause or consequence of muscle dysfunction.

We used three laminopathy mouse models coupled with an *in vitro* muscle differentiation platform⁷ and high resolution time-lapse microscopy to systematically study the link between impaired NE structure, damage, and muscle cell dysfunction. *Lmna* mutant myonuclei exhibited progressive NE damage, including chromatin protrusions and transient NE rupture. Intriguingly, NE rupture was associated with progressive DNA damage and DNA damage response activation, which was also observed in patient biopsies. Disrupting the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex, which physically connects the nucleus to the cytoskeleton⁸, prevented nuclear envelope rupture, reduced DNA damage, and rescued myofiber viability and contractility in lamin A/C-deficient cells. These findings indicate a causative role of NE rupture and DNA damage in progressive muscle decline and provide an explanation for how lamin A/C mutations lead to muscle weakness and wasting in muscle laminopathies.

RESULTS

***Lmna* mutations cause progressive decline in myofiber health**

To examine the effect of *Lmna* mutations on nuclear mechanics and muscle function, we isolated myoblasts from three mouse models of striated muscle laminopathies, representing a spectrum of disease severity (**Figure 1a**, Supplementary Figure 1): Lamin A/C-deficient (*Lmna*^{-/-})⁹, referred to as lamin A/C knock-out (*Lmna* KO), *Lmna*^{N195K/N195K} knock-in (*Lmna* N195K)¹⁰, *Lmna*^{H222P/H222P} knock-in (*Lmna* H222P)¹¹ mice, and wild-type littermates. While the *Lmna* N195K mice were originally described as a model for dilated cardiomyopathy¹⁰, in the C57BL/6 background they also developed muscular dystrophy (Supplementary Figure 1). For *in vitro* studies, we used a three-dimensional culture protocol to differentiate primary myoblasts into mature, contractile myofibers (**Figure 1b,c**; Supplementary Figure 2)⁷. All myoblasts successfully differentiated into myotubes and myofibers (**Figure 1c**). Wild-type myofibers remained healthy and highly contractile at ten days of differentiation (Supplementary Movie 1). In contrast, *Lmna* KO myofibers declined in contractility, viability, and number of myonuclei, starting at day five of differentiation; the *Lmna* N195K myofibers showed similar declines by day ten of differentiation, whereas *Lmna* H222P myofibers had no significant decline by day ten (**Figure 1c,d**; Extended Data Figure 1, Supplementary Movies 2-4). The decreased viability in *Lmna* KO and N195K myofibers was associated with increased caspase-3 activity (**Figure 1e,f**). Together, these assays

revealed a striking correlation between the defects observed *in vitro* with the severity of the disease in the corresponding mouse models.

***Lmna* mutant muscle cells have reduced nuclear stability**

To test whether the progressive deterioration of *Lmna* mutant myofibers results from mechanically weakened myonuclei, we measured nuclear deformability in primary myoblasts using a microfluidic micropipette aspiration assay¹² (**Figure 2a**, Supplementary Movie 5). Nuclei from *Lmna* KO and N195K myoblasts were much more deformable than nuclei from wild-type myoblasts; in contrast, *Lmna* H222P myonuclei had only modestly increased deformability (**Figure 2b,c**; Supplementary Figure 3a). Ectopic lamin A expression rescued nuclear deformability in *Lmna* KO myoblasts (Supplementary Figure 3b-d), confirming that impaired nuclear stability results from loss of lamin A/C. Myoblasts from dystrophin-mutant *Mdx* mice had normal nuclear deformability (Supplementary Figure 4), indicating that reduced nuclear stability is specific to *Lmna* mutations, not muscular dystrophy in general.

As a second approach to examine nuclear stability in mature myofibers, we measured nuclear deformability in response to perinuclear force application¹³. *Lmna* KO myofibers exhibited increased nuclear deformability compared with wild-type controls (**Figure 2d,e**; Supplementary Movie 6). Furthermore, *Lmna* mutant myofibers had significantly elongated myonuclei compared to wild-type controls (**Figure 2f,g**), consistent with previous reports from laminopathy patients¹⁴.

***Lmna* mutant myonuclei display chromatin protrusions**

Despite possessing mechanically weak nuclei, *Lmna* mutant myoblasts initially displayed normal nuclear morphology. During differentiation, however, *Lmna* mutant myofibers exhibited striking chromatin protrusions (**Figure 3a,b**). The protrusions were enclosed by nuclear membranes, as evidenced by the presence of the nuclear membrane protein emerin, but lacked nuclear pores and other NE proteins (Supplementary Figure 5a,b). The chromatin protrusions were most prevalent in *Lmna* KO myofibers, followed by *Lmna* N195K, and then *Lmna* H222P myofibers (**Figure 3b**), correlating with the increased nuclear deformability *in vitro* and the disease severity *in vivo*. Expression of lamin A in *Lmna* KO myoblasts reduced the occurrence of chromatin protrusions (**Figure 3b**). Single muscle fibers isolated from the hindlimbs of *Lmna* KO exhibited similar NE defects, validating their presence *in vivo* (**Figure 3c,d**). Interestingly, the prevalence of chromatin protrusions in the *Lmna* KO myonuclei was higher at the myotendinous junctions (MTJ) than in the muscle fiber body (**Figure 3d**), consistent with a previous report of nuclear abnormalities at the MTJ in *Lmna* KO mice¹⁵.

Nuclear damage is intrinsic to lamin A/C-deficient nuclei

To address whether the observed NE defects are nucleus-intrinsic or arise from other changes in the *Lmna* mutant cells, we generated “hybrid” myofibers containing both wild-type and *Lmna* KO nuclei (Extended Data Figure 2a) by combining *Lmna* KO and wild-type myoblasts prior to differentiation. Hybrid myofibers containing ~20% of *Lmna* KO nuclei appeared healthy. Nonetheless, *Lmna* KO nuclei within the hybrid myofibers showed the same relative frequency of chromatin protrusions as nuclei from isogenic *Lmna* KO myofibers (Extended Data Figure 2b).

Wild-type nuclei were not adversely affected in the hybrid myofibers. These results indicate that defects in nuclear structure are intrinsic to the *Lmna* mutant myonuclei and not due to altered cytoplasmic signaling or changes in the cytoplasmic architecture in *Lmna* mutant muscle fibers.

***Lmna* mutant myofibers exhibit extensive NE rupture**

To examine whether reduced nuclear stability leads to increased NE rupture, we modified myoblasts to co-express fluorescently labeled histones (H2B-tdTomato) and a NE rupture reporter, consisting of a green fluorescent protein with a nuclear localization signal (NLS-GFP)¹⁶. *Lmna* KO myotubes frequently exhibited NE rupture, indicated by transient loss of nuclear NLS-GFP (Supplementary Figure 6, Supplementary Movie 7). Experiments using a second NE rupture reporter, cGAS-mCherry, which accumulates at the rupture site and persists after NE repair^{16, 17}, confirmed a progressive increase in NE rupture in *Lmna* KO myotubes during differentiation that was rescued by re-introduction of wild-type lamin A (**Figure 3e,f**). *Lmna* N195K cells showed intermediate levels of NE rupture, whereas cGAS-mCherry accumulation in *Lmna* H222P myotubes was indistinguishable from wild-type controls (Extended Data Figure 3a,b).

To validate these results *in vivo*, we generated transgenic mice expressing a fluorescent cGAS-tdTomato NE rupture reporter and crossed these mice into the *Lmna* mutant mouse models. Muscle fibers from *Lmna* KO and *Lmna* N195K mice expressing the cGAS-tdTomato reporter (cGAS+) revealed a large fraction of myonuclei with cGAS-tdTomato foci, which were absent in both cGAS+ wild-type littermates and in cGAS- *Lmna* KO muscle fibers (**Figure 3d-e**; Extended Data Figure 3c). The frequency of NE rupture was increased at the MTJ compared to the muscle fiber body (**Figure 3e**; Extended Data Figure 3; Supplementary Figure 7), paralleling the increased chromatin protrusions at the MTJs. cGAS-tdTomato accumulation in the different mouse models correlated with disease severity (Extended Data Figure 3c). As an independent measure of nuclear envelope integrity, we analyzed nuclear localization of heat shock protein 90 (Hsp90), which is normally excluded from the nucleus¹⁸. Whereas Hsp90 was mostly cytoplasmic in wild-type myofibers, *Lmna* mutant models had increased nuclear Hsp90 accumulation (Supplementary Figure 8a-d).

***Lmna* KO myonuclei have increased levels of DNA damage**

Nuclear deformation and NE rupture can cause DNA damage in migrating cells^{16, 17, 19}. Quantifying DNA damage in differentiating myoblasts by staining for γ H2AX revealed elevated levels of DNA damage at the onset of differentiation (**Figure 4a,b**), consistent with previous reports^{20, 21}. However, while DNA damage in wild-type cells returned to baseline, the fraction of *Lmna* KO cells with severe DNA damage continued to increase with differentiation (**Figure 4b**). In addition, *Lmna* KO myotubes exhibited increased activity of the DNA-dependent protein kinase (DNA-PK) (**Figure 4c**). Muscle fibers isolated from *Lmna* KO mice confirmed increased γ H2AX accumulation and increased DNA-PK activity, especially at the MTJ (**Figure 4d-f**, Supplementary Figure 9). Of the myonuclei with extensive γ H2AX staining, >80% had chromatin protrusions, suggesting a link between NE damage and DNA damage (Extended Data Figure 4). Muscle fibers from *Lmna* N195K mice had similar levels of DNA damage as *Lmna* KO mice, whereas DNA damage was less severe in the *Lmna* H222P animals (**Figure 4d,e**), correlating with disease severity.

To address whether the accumulation of DNA damage during *in vitro* differentiation of *Lmna* KO myoblasts was caused by new nuclear damage or defects in DNA damage repair^{22, 23}, we subjected *Lmna* KO and wild-type myofibers to gamma irradiation and monitored changes in γ H2AX levels for 24 hours post-treatment. *Lmna* KO myofibers displayed a DNA damage repair profile nearly identical to wild-type controls (Extended Data Figure 5), suggesting that their ability to repair DNA damage is not significantly impaired.

Accumulation of DNA damage correlates with myofiber death

To test whether accumulation of DNA damage is sufficient to decrease myofiber viability, we treated *Lmna* KO and wild-type myofibers with phleomycin, a radiation mimetic agent, in conjunction with inhibition of DNA damage repair by treatment with NU7441, a DNA-PK-specific inhibitor, and/or KU55933, an ATM-specific inhibitor (**Figure 4g**). The combined treatment led to accumulation of DNA damage and reduced viability in wild-type myofibers, comparable to that observed in untreated *Lmna* KO cells (**Figure 4h,i**; Supplementary Figure 10). In contrast, phleomycin, alone or in combination with the inhibition of DNA damage repair, did not further reduce viability in *Lmna* KO myofibers (Supplementary Figure 10), suggesting that the preexisting DNA damage in these cells is sufficient to cause myofiber decline.

Microtubule stabilization reduces *Lmna* KO nuclear damage

In striated muscle cells, the microtubule network forms a cage-like structure around the nucleus (Supplementary Figure 11)^{24, 25}. To test if stabilizing this microtubule network, and thereby reinforcing myonuclei, could reduce NE damage, we treated *in vitro* differentiated *Lmna* KO myoblasts with the microtubule stabilizing drug paclitaxel. Paclitaxel treatment reduced deformation in *Lmna* KO myonuclei (Extended Data Figure 6a,b; Supplementary Movie 8) and lowered the percentage of nuclei with chromatin protrusions and NE rupture (Extended Data Figure 6c,d), suggesting that nuclear damage arises from mechanical stress on the myonuclei.

Nuclear movement causes NE damage in *Lmna* KO myotubes

Mechanical stress may be imparted to myonuclei via actomyosin-mediated contractile forces, and/or forces due to nuclear movement during myoblast fusion, microtubule-driven spacing, and shuttling/anchoring to the myofiber periphery^{24, 26, 27}. To determine if NE damage in myotubes was caused by actomyosin contractility, we treated *Lmna* KO and wild-type myotubes with nifedipine, a muscle-specific calcium channel blocker. Nifedipine treatment abrogated myotube contraction, but did not reduce chromatin protrusions and NE ruptures in *Lmna* KO myonuclei (Extended Data Figure 7), indicating that actomyosin contractility is not required to induce NE damage.

Since NE rupture (**Figure 3f**) and chromatin protrusions coincided with myotube maturation (Supplementary Figure 12) and myonuclear migration (**Figure 5a**; Supplementary Movie 9), we sought to determine if we could prevent NE damage by depletion of Kif5b, a subunit of kinesin-1 required for nuclear migration in myotubes^{24, 26, 27}. Kif5b depletion nearly abolished chromatin protrusions, NE rupture, and severe DNA damage in the *Lmna* KO myotubes (**Figure 5b,c**; Extended Data Figure 8), indicating that nuclear movement by microtubule-associated motors is

sufficient to cause nuclear damage in *Lmna* mutant myofibers, and that eliminating NE rupture reduces DNA damage in these cells.

LINC complex disruption improves *Lmna* KO myofiber function

We hypothesized that reducing cytoskeletal forces on the myonuclei would improve myofiber health. Since depletion of Kif5b has detrimental long-term effects on myofiber function²⁵, we disrupted the LINC complex through inducible expression of a dominant negative GFP-KASH2 (DN-KASH) protein²⁸ (Extended Data Figure 9a,b). A construct containing a two amino acid extension (DN-KASHext) that targets to the NE but does not disrupt the LINC complex²⁸ served as control (Extended Data Figure 9a). As expected, expression of DN-KASH, but not DN-KASHext, reduced nuclear migration (Extended Data Figure 9b). While DN-KASH expression had no effect on contractility or viability in *Lmna* WT myofibers, in *Lmna* KO cells it reduced chromatin protrusions, NE ruptures, and the number of cells with severe DNA damage, and improved cell viability and contractility (**Figure 5d-h**, Extended Data Figure 9c-g; Supplementary Movies 10-17). These findings support the model that mechanical forces induce NE rupture and DNA damage in *Lmna* mutant myofibers, leading to myofiber dysfunction and death.

Human laminopathy muscle biopsies have increased DNA damage

To corroborate our findings in the mouse models, we examined skeletal muscle biopsy samples from humans with *LMNA*-related muscular dystrophies and age-matched controls (Supplementary Table 1). Muscle cryosections were immunofluorescently labeled for 53BP1, an established marker for DNA double strand breaks²⁹, and myofiber nuclei were identified based on labeling for DNA, actin, and dystrophin (**Figure 6a,b**, Supplementary Figure 13). Intriguingly, tissues from individuals with the most severe forms of the muscular dystrophy, i.e., those with early childhood and juvenile onsets, had increased DNA damage compared to age-matched controls (**Figure 6c-e**), closely mirroring the findings in the severe laminopathy mouse models (**Figure 4e**).

DISCUSSION

The mechanisms by which *LMNA* mutations result in muscle-specific diseases have long puzzled researchers and clinicians, presenting a major hurdle in the development of effective treatments. Our data revealed a striking correlation between NE defects and DNA damage in myonuclei and disease severity in three mouse models of striated muscle laminopathies. Muscle biopsy tissue from individuals with *LMNA* muscular dystrophies showed a similar trend, with the most severe cases of muscular dystrophy having the highest levels of DNA damage. Our data are consistent with previous reports of NE damage in laminopathic skeletal and cardiac muscle, and tendons^{9, 30-37}. We now link these findings to a mechanism that may explain the muscle-specific defects in many laminopathies: cytoskeletal forces cause chromatin protrusions and NE ruptures in mechanically weakened *Lmna* mutant muscle cell nuclei, triggering DNA damage and DNA damage response activation, which then leads to myofiber dysfunction and death (Extended Data Figure 10). Other mechanisms, which may be mutation specific, likely add to the pathogenesis of laminopathies.

Increased DNA damage and altered DNA damage repair have been reported previously in progeroid laminopathies^{22, 23, 38}, but not AD-EDMD and *LMNA*-CMD. The precise mechanisms by which NE rupture causes DNA damage and cell death remain to be elucidated. The DNA damage could arise from exposure of genomic DNA to cytoplasmic nucleases and/or nuclear exclusion and efflux of DNA repair factors^{39, 40}. Our findings strongly indicate that DNA damage is linked to mechanically induced NE defects. Although we observed similar DNA damage repair dynamics between irradiated *Lmna* KO and wild-type myofibers, different types of DNA damage can elicit distinct repair responses in muscle cells⁴¹. Thus, *Lmna* mutant cells may experience impaired DNA damage repair²³. In addition, decreased DNA repair efficiency over the course of differentiation⁴² may exacerbate the DNA damage in *Lmna* mutant myofibers.

DNA damage results in rapid activation of DNA damage response pathways, including DNA-PK and ATM, leading to the stabilization of p53 that can induce cell cycle arrest, senescence, and apoptosis.⁴³ Increased activity of DNA-PK is associated with age-related decline of metabolic, mitochondrial, and physical fitness of skeletal muscle cells¹⁸. Furthermore, deletion of p53 improved cardiac defects and, to lesser degree, survival in a cardiac-specific laminopathy mouse model³⁸. Consistent with DNA damage-induced p53 signaling, we observed caspase-3 activation and reduced viability in *Lmna* KO and N195K myofibers. While the mechanisms controlling apoptosis in a post-mitotic tissue such as skeletal muscle are unclear⁴⁴, this type of cell death has been observed in myofiber wasting⁴⁵ and hearts of *Lmna* mutant mice^{38, 46, 47}.

Although we cannot exclude the possibility that altered cytoplasmic signaling and gene regulation contribute to the increased NE rupture and DNA damage in *Lmna* mutant muscle cells^{23, 38}, our data suggest that the damage is mechanically induced and nucleus-intrinsic. Surprisingly, we found that nuclear damage during *in vitro* myofiber differentiation was associated with microtubule-associated movements and not actomyosin contractions. Nonetheless, mature muscle cells *in vivo* can generate substantially higher contractile forces than *in vitro* differentiated cells; thus, actomyosin contractility is likely to contribute to NE rupture and DNA damage in skeletal and cardiac tissues³⁷. In addition, *LMNA* mutations could disrupt perinuclear cytoskeletal organization, including desmin³⁴ and microtubule networks, thereby further destabilizing myonuclei and promoting mechanical NE damage.

Our findings indicate potential targets for disease intervention. Paclitaxel was recently reported to improve cardiac conduction defects in *Lmna* H222P mice by restoring connexin 43 localization⁴⁸. Here, we identified an additional mechanism by which microtubule stabilization can mitigate damage in striated muscle laminopathies. Cell signaling pathways activated by DNA damage, such as DNA-PK¹⁸ and p53³⁸, may provide additional targets to ameliorate muscle wasting. In addition, disruption of the LINC complex may offer a specific approach to reduce mechanical stress on myonuclei and improve muscle function.

Insights gained from this work are also relevant to other biological systems in which nuclei are exposed to physical stress, such as in confined migration and nuclear movement in polarized epithelial or neuronal cells⁴⁹. For example, neuronal cells lacking lamin A/C⁵⁰ or B-type lamins⁵¹ may be more susceptible to kinesin-mediated nuclear damage, leading to neurodevelopmental defects. Taken together, these findings highlight a mechanism by which weakened myonuclei experience microtubule-mediated NE damage, leading to DNA damage and muscle dysfunction, potentially explaining the phenotypes seen in striated muscle laminopathies and a spectrum of other diseases caused by NE defects.

FIGURE LEGENDS

Figure 1. *In vitro* differentiated primary myoblasts from *Lmna* KO, *Lmna* N195K, and *Lmna* H222P mice recapitulate disease severity. (a) Graphical representation of the disease severity in the three *Lmna* mutant models used in the study, showing the published 50% mortality rates of *Lmna* KO, *Lmna* N195K, and *Lmna* H222P mice, as well as wild-type (*Lmna* WT) controls. Shading represents the onset of disease symptoms in the mouse models. (b) Schematic diagram representing the stages of differentiation (primary myoblasts to mature myofibers) in the *in vitro* system. (c) Representative images of *Lmna* WT, *Lmna* KO, *Lmna* N195K and *Lmna* H222P primary skeletal muscle cells at days 0, 5 and 10 of differentiation. Scale bar: 100 μ m. Experiments were conducted three times with similar results. (d) Quantification of cell viability using MTT assay at days 5 and 10 of differentiation. Data points indicate results from *n* independent primary cell lines for each genotype. Significance was determined by one-way ANOVA within each time point, using Tukey's correction for multiple comparisons. (e) Representative image of cleaved caspase-3 immunofluorescence in *Lmna* WT and *Lmna* KO myofibers at day 10 of differentiation. Scale bar: 20 μ m (f) Quantification of cleaved caspase-3 relative to myosin heavy chain immunofluorescence area in *Lmna* WT, *Lmna* KO, *Lmna* N195K and *Lmna* H222P myofibers after 10 days of differentiation. Data points are for *n* independent primary cell lines for each genotype. Significance was determined by one-way ANOVA, using Tukey's correction for multiple comparisons. All bar plots show mean value $\pm$ standard error of the mean.

Figure 2. *Lmna* mutant muscle cells have reduced nuclear stability. (a) Representative images of *Lmna* WT and *Lmna* KO nuclei deforming in a microfluidic micropipette aspiration device. Scale bar: 10 μ m. (b, c) Measurements for nuclear deformation at 5 second intervals (b) for *Lmna* WT, *Lmna* KO, *Lmna* N195K, and *Lmna* H222P myoblasts during 60 seconds of aspiration. Quantification of the nuclear deformation after 60 seconds of aspiration (c). Data points are for *n* nuclei per genotype from three independent experiments. Significance was determined by one-way ANOVA, using Tukey's correction for multiple comparisons. (d) A microharpoon assay was used to measure nuclear deformability ($\Delta L/L_0$) in myofibers, showing representative images before and at the end of perinuclear force application with a microneedle (dashed line). Scale bar: 15 μ m. (e) Quantification of nuclear strain induced by the microharpoon assay in *Lmna* WT and *Lmna* KO myotubes at day 5 of differentiation. Data points are from *n* nuclei per genotype from three independent experiments. Significance was determined by two-tailed student's *t*-test. (f) Representative images of nuclear morphology in *Lmna* WT, *Lmna* KO, *Lmna* N195K, and *Lmna* H222P myotubes after 5 days of differentiation. Scale bar: 20 μ m. (g) Nuclear aspect ratio (length/width) in *Lmna* WT, *Lmna* KO, *Lmna* N195K, and *Lmna* H222P myotubes after 5 days of differentiation. Data points are for *n* independent primary cell lines for each genotype, with >100 nuclei counted per cell line. Significance was determined by one-way ANOVA, using Tukey's correction for multiple comparisons. Bar plots show mean value $\pm$ standard error of the mean.

Figure 3. *Lmna* mutant myonuclei exhibit chromatin protrusions and NE ruptures. (a) Representative images of chromatin protrusions (arrowheads) in *Lmna* KO myofibers after 10 days of differentiation. Yellow arrowheads indicate protrusion end. Scale bar: 10 μ m. (b) Percentage of myonuclei containing chromatin protrusion at days 5 and 10 of differentiation. *n* = 3 independent experiments; 62-73 nuclei quantified per genotype. Significance determined by one-way ANOVA

within each time point, using Tukey's correction for multiple comparisons. (c) Representative images of single muscle fibers from *Lmna* WT and *Lmna* KO mice. Arrowheads indicate chromatin protrusions. Scale bar: 20 μ m. (d) Percentage of myonuclei with chromatin protrusion in muscle fibers from *Lmna* WT and *Lmna* KO mice. Left, whole muscle fibers; right, analysis for nuclei located at the MTJ versus fiber body. Data based on *n* individual myofibers per genotype, isolated from 5-11 animals each. Significance determined by two-tailed student's *t*-test (total chromatin protrusions) or two-way ANOVA (genotype; MTJ/body) using Tukey's correction for multiple comparisons. (e) Representative images of cGAS-mCherry accumulation at sites of NE rupture in *Lmna* KO myonuclei at day 5 of differentiation. Scale bar: 20 μ m. (f) Formation of cGAS-mCherry foci per field of view during myofiber differentiation in *Lmna* WT, *Lmna* KO, and *Lmna* KO cells expressing ectopic lamin A, based on three independent experiments per group. Significance determined by non-linear regression analysis. (g) Representative images of single muscle fibers from *Lmna* WT and *Lmna* KO mice expressing cGAS-tdTomato NE rupture reporter, showing accumulation of cGAS-tdTomato (arrowhead) at sites of NE rupture. Scale bar: 10 μ m. (h) Percentage of myonuclei with cGAS-tdTomato foci in isolated muscle fibers from *Lmna* WT and *Lmna* KO mice expressing the cGAS-tdTomato transgene (cGAS+) or non-expressing littermates (cGAS-). The latter served as control for potential autofluorescence. Analysis performed for whole fiber (left) and by classification of nuclei located at the MTJ or fiber body (right). Data based on *n* individual myofibers per genotype, isolated from 5 animals each. Significance determined by one-way ANOVA or two-way ANOVA (genotype; MTJ/body) using Tukey's correction for multiple comparisons. All bar plots show mean value $\pm$ standard error of the mean.

Figure 4. *Lmna* KO myonuclei have increased DNA damage *in vitro* and *in vivo*. (a) Representative images of γ H2AX foci in *Lmna* KO myonuclei. Arrowheads indicated γ H2AX foci in chromatin protrusions. Scale bar: 10 μ m. (b) Quantification of DNA damage based on the number of γ H2AX foci per nucleus, for *n* independent primary cell lines per genotype. (c) Quantification of DNA-PK activity in *Lmna* WT and *Lmna* KO myotubes at day 5 of differentiation by probing for phosphorylated DNA-PK (pS2053), based on lysates from *n* independent cell lines. Significance determined by two-way ANOVA (genotype; time-point), using Tukey's correction for multiple comparisons. (d) Representative images of γ H2AX foci in isolated single muscle fibers from *Lmna* WT and *Lmna* KO mice. Scale bar: 10 μ m. (e) Extent of DNA damage based on the number of γ H2AX foci per nucleus in isolated single fibers. *n* indicates number of mice per genotype, with 5 fibers imaged per animal. (f) Representative image of phosphorylated DNA-PK (pS2053) in isolated muscle fibers from *Lmna* WT and *Lmna* KO mice. Scale bar: 20 μ m. (g) Representative image of γ H2AX foci following treatment with phleomycin, with or without DNA-PK and ATM inhibition. Scale bar: 10 μ m. (h) Quantification of DNA damage based on the number of γ H2AX foci per nucleus for *Lmna* WT cells treated with phleomycin, with or without DNA-PK and ATM inhibition. *n* = 3 independent experiments per condition. (i) Quantification of viability in *Lmna* WT myofibers using MTT assay following DNA damage induction with phleomycin, with and without concurrent treatment with DNA-PK (NU7441) and/or ATM (KU55933) inhibition, based on *n* independent experiments per condition. Significance determined by one-way ANOVA, using Tukey's correction for multiple comparisons. Dashed red line indicates the corresponding results for the *Lmna* KO untreated control. All bar plots show mean value $\pm$ standard error of the mean.

Figure 5. Reducing forces on myonuclei prevents NE rupture and improves viability and contractility in *Lmna* KO myotubes. (a) Representative time-lapse sequence of NE rupture during nuclear migration in *Lmna* KO myonuclei (day five of differentiation). Arrowheads mark two nuclei that undergo NE rupture, visible by transient loss of NLS-GFP from the nucleus and stable accumulation of cGAS-mCherry at the site of rupture (red arrow). Right, close-ups of the nucleus marked with the yellow arrowheads. Scale bar: 10 μ m for all images. (b) Representative images of cGAS-mCherry accumulation in *Lmna* KO cells treated with either non-target control siRNA (siRNA NT) or siRNA against Kif5b. Scale bar: 20 μ m (c) Percentage of *Lmna* KO myonuclei positive for cGAS-mCherry foci, following treatment with either non-target (NT) siRNA or siRNA against Kif5b, based on *n* independent experiments, in which a total of 911-1383 nuclei per condition were quantified. Significance determined by two-way ANOVA (genotype; siRNA treatment), using Tukey's correction for multiple comparisons. (d) Number of cGAS-mCherry foci/area in *Lmna* KO expressing either DN-KASH2 or DN-KASH2ext, treated with or without doxycycline (DOX) from day 3 until day 10 of differentiation, based on three independent experiments per condition. (e) Number of cGAS-mCherry foci/area at 10 days of differentiation, based on *n* independent experiments per condition. Significance determined by two-way ANOVA (genotype; DOX treatment), using Tukey's correction for multiple comparisons. (f) Cell viability measured by MTT assay in *Lmna* KO cells expressing either DN-KASH2 or DN-KASH2ext. Data for *n* replicates per condition, from three independent experiments. Significance was determined by two-way ANOVA (genotype; DOX treatment), using Tukey's correction for multiple comparisons. (g) Contractility of *Lmna* KO myofibers expressing either DN-KASH or DN-KASHext, based on *n* independent experiments, for which scores were determined based on 5-6 image sequences per condition. Significance was determined by two-way ANOVA (genotype; DOX treatment), using Tukey's correction for multiple comparisons. All bar plots show mean value $\pm$ standard error of the mean.

Figure 6. Human muscle biopsy tissues from individuals with *LMNA* muscular dystrophy have increased DNA damage. Cryopreserved human muscle biopsy tissues from individuals with *LMNA* muscular dystrophy and age-matched controls were stained for either (a) 53BP1, DAPI, and phalloidin or (b) 53BP1, DAPI, and dystrophin. Arrowheads denote nuclei within muscle fibers, identified by dystrophin labeling of the muscle fiber membrane. Each muscular dystrophy patient possesses a *LMNA* point mutation producing a single amino acid substitution (Supplementary Table 1). The *LMNA* mutations cause reduced fiber size, abnormally shaped fibers, and increased nuclear 53BP1 staining. Scale bar: 30 μ m. (c-e) Patients were stratified based on the age at time of tissue collection. The nuclear intensity values of 53BP1 were binned into 11 categories based on the level of intensity (color coding on the right). The X-axis shows the mutant lamin A/C expressed in individuals with an *LMNA* mutation and the age-matched control samples expressing wild-type lamin A/C. The Y-axis represents the relative percent intensity of 53BP1 staining quantified using ImageJ. The intensity values did not meet the criteria for a normal distribution. For panel (c) a two-sided Kruskal-Wallis one-way analysis of variance (ANOVA), followed by the two-sided Dunn post hoc test, were used to determine if there was a significant difference in staining among the genotypes. For panels (d) and (e) a two-sided Mann-Whitney

non-parametric test was used for comparisons. n indicates the number of nuclei scored per patient. All bar plots show mean value $\pm$ standard error of the mean.

REFERENCES

1. de Leeuw, R., Gruenbaum, Y. & Medalia, O. Nuclear Lamins: Thin Filaments with Major Functions. *Trends Cell Biol* **28**, 34-45 (2018).
2. Davidson, P.M. & Lammerding, J. Broken nuclei--lamins, nuclear mechanics, and disease. *Trends Cell Biol* **24**, 247-256 (2014).
3. Maggi, L., Carboni, N. & Bernasconi, P. Skeletal Muscle Laminopathies: A Review of Clinical and Molecular Features. *Cells* **5** (2016).
4. Emery, A.E. Emery-Dreifuss muscular dystrophy - a 40 year retrospective. *Neuromuscular disorders : NMD* **10**, 228-232 (2000).
5. Zwerger, M. *et al.* Myopathic lamin mutations impair nuclear stability in cells and tissue and disrupt nucleocytoskeletal coupling. *Hum Mol Genet* **22**, 2335-2349 (2013).
6. Gruenbaum, Y. & Foisner, R. Lamins: nuclear intermediate filament proteins with fundamental functions in nuclear mechanics and genome regulation. *Annual review of biochemistry* **84**, 131-164 (2015).
7. Pimentel, M.R., Falcone, S., Cadot, B. & Gomes, E.R. In Vitro Differentiation of Mature Myofibers for Live Imaging. *Journal of visualized experiments : JoVE* (2017).
8. Lombardi, M.L. *et al.* The interaction between nesprins and sun proteins at the nuclear envelope is critical for force transmission between the nucleus and cytoskeleton. *Journal of Biological Chemistry* **286**, 26743-26753 (2011).
9. Sullivan, T. *et al.* Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. *J Cell Biol* **147**, 913-920 (1999).
10. Mounkes, L.C., Kozlov, S.V., Rottman, J.N. & Stewart, C.L. Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. *Hum Mol Genet* **14**, 2167-2180 (2005).
11. Arimura, T. *et al.* Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. *Hum Mol Genet* **14**, 155-169 (2005).
12. Davidson, P.M. *et al.* High-throughput microfluidic micropipette aspiration device to probe time-scale dependent nuclear mechanics in intact cells. *Lab Chip* **19**, 3652-3663 (2019).
13. Fedorchak, G. & Lammerding, J. Cell Microharpooning to Study Nucleo-Cytoskeletal Coupling. *Methods in molecular biology* **1411**, 241-254 (2016).
14. Tan, D. *et al.* Phenotype-Genotype Analysis of Chinese Patients with Early-Onset LMNA-Related Muscular Dystrophy. *PLoS One* **10**, e0129699 (2015).
15. Gnocchi, V.F. *et al.* Uncoordinated transcription and compromised muscle function in the lmna-null mouse model of Emery-Dreifuss muscular dystrophy. *PLoS One* **6**, e16651 (2011).
16. Denais, C.M. *et al.* Nuclear envelope rupture and repair during cancer cell migration. *Science* **352**, 353-358 (2016).
17. Raab, M. *et al.* ESCRT III repairs nuclear envelope ruptures during cell migration to limit DNA damage and cell death. *Science* **352**, 359-362 (2016).
18. Park, S.-J. *et al.* DNA-PK promotes the mitochondrial, metabolic, and physical decline that occurs during aging. *Cell metabolism* **25**, 1135-1146. e1137 (2017).
19. Irianto, J. *et al.* Nuclear constriction segregates mobile nuclear proteins away from chromatin. *Mol Biol Cell* **27**, 4011-4020 (2016).

20. Larsen, B.D. *et al.* Caspase 3/caspase-activated DNase promote cell differentiation by inducing DNA strand breaks. *Proc Natl Acad Sci U S A* **107**, 4230-4235 (2010).
21. Connolly, P.F. & Fearnhead, H.O. DNA-PK activity is associated with caspase-dependent myogenic differentiation. *Febs Journal* **283**, 3626-3636 (2016).
22. Burla, R., La Torre, M., Merigliano, C., Verni, F. & Saggio, I. Genomic instability and DNA replication defects in progeroid syndromes. *Nucleus* **9**, 368-379 (2018).
23. Graziano, S., Kreienkamp, R., Coll-Bonfill, N. & Gonzalo, S. Causes and consequences of genomic instability in laminopathies: Replication stress and interferon response. *Nucleus* **9**, 258-275 (2018).
24. Roman, W. & Gomes, E.R. Nuclear positioning in skeletal muscle. *Seminars in cell & developmental biology* **82**, 51-56 (2018).
25. Starr, D.A. Muscle Development: Nucleating Microtubules at the Nuclear Envelope. *Current biology : CB* **27**, R1071-R1073 (2017).
26. Folker, E.S. & Baylies, M.K. Nuclear positioning in muscle development and disease. *Front Physiol* **4**, 363 (2013).
27. Bone, C.R. & Starr, D.A. Nuclear migration events throughout development. *J Cell Sci* **129**, 1951-1961 (2016).
28. Stewart-Hutchinson, P.J., Hale, C.M., Wirtz, D. & Hodzic, D. Structural requirements for the assembly of LINC complexes and their function in cellular mechanical stiffness. *Exp Cell Res* **314**, 1892-1905 (2008).
29. Loewer, A., Karanam, K., Mock, C. & Lahav, G. The p53 response in single cells is linearly correlated to the number of DNA breaks without a distinct threshold. *BMC biology* **11**, 114 (2013).
30. Fidzianska, A. & Hausmanowa-Petrusewicz, I. Architectural abnormalities in muscle nuclei. Ultrastructural differences between X-linked and autosomal dominant forms of EDMD. *J Neurol Sci* **210**, 47-51 (2003).
31. Park, Y.E. *et al.* Nuclear changes in skeletal muscle extend to satellite cells in autosomal dominant Emery-Dreifuss muscular dystrophy/limb-girdle muscular dystrophy 1B. *Neuromuscular disorders : NMD* **19**, 29-36 (2009).
32. Gupta, P. *et al.* Genetic and ultrastructural studies in dilated cardiomyopathy patients: a large deletion in the lamin A/C gene is associated with cardiomyocyte nuclear envelope disruption. *Basic research in cardiology* **105**, 365-377 (2010).
33. Sylvius, N. *et al.* In vivo and in vitro examination of the functional significances of novel lamin gene mutations in heart failure patients. *J Med Genet* **42**, 639-647 (2005).
34. Nikolova, V. *et al.* Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. *The Journal of clinical investigation* **113**, 357-369 (2004).
35. Uchino, R., Nonaka, Y.K., Horigome, T., Sugiyama, S. & Furukawa, K. Loss of Drosophila A-type lamin C initially causes tendon abnormality including disintegration of cytoskeleton and nuclear lamina in muscular defects. *Dev Biol* **373**, 216-227 (2013).
36. Dialynas, G. *et al.* LMNA variants cause cytoplasmic distribution of nuclear pore proteins in Drosophila and human muscle. *Hum Mol Genet* **21**, 1544-1556 (2012).
37. Cho, S. *et al.* Mechanosensing by the Lamina Protects against Nuclear Rupture, DNA Damage, and Cell-Cycle Arrest. *Dev Cell* **49**, 920-935 e925 (2019).

38. Chen, S.N. *et al.* DNA Damage Response/TP53 Pathway Is Activated and Contributes to the Pathogenesis of Dilated Cardiomyopathy Associated With LMNA (Lamin A/C) Mutations. *Circ Res* **124**, 856-873 (2019).
39. Hatch, E.M. Nuclear envelope rupture: little holes, big openings. *Curr Opin Cell Biol* **52**, 66-72 (2018).
40. Irianto, J. *et al.* DNA Damage Follows Repair Factor Depletion and Portends Genome Variation in Cancer Cells after Pore Migration. *Current biology : CB* **27**, 210-223 (2017).
41. Fortini, P. *et al.* DNA damage response by single-strand breaks in terminally differentiated muscle cells and the control of muscle integrity. *Cell death and differentiation* **19**, 1741-1749 (2012).
42. Ferdousi, L.V. *et al.* More efficient repair of DNA double-strand breaks in skeletal muscle stem cells compared to their committed progeny. *Stem Cell Research* **13**, 492-507 (2014).
43. Kruiswijk, F., Labuschagne, C.F. & Vousden, K.H. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. *Nature reviews. Molecular cell biology* **16**, 393-405 (2015).
44. Schwartz, L.M. Skeletal Muscles Do Not Undergo Apoptosis During Either Atrophy or Programmed Cell Death-Revisiting the Myonuclear Domain Hypothesis. *Frontiers in Physiology* **9**, 1887 (2019).
45. Cheema, N., Herbst, A., McKenzie, D. & Aiken, J.M. Apoptosis and necrosis mediate skeletal muscle fiber loss in age-induced mitochondrial enzymatic abnormalities. *Aging Cell* **14**, 1085-1093 (2015).
46. Lu, D. *et al.* LMNA E82K mutation activates FAS and mitochondrial pathways of apoptosis in heart tissue specific transgenic mice. *PLoS One* **5**, e15167 (2010).
47. Wolf, C.M. *et al.* Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. *Journal of Molecular and Cellular Cardiology* **44**, 293-303 (2008).
48. Macquart, C. *et al.* Microtubule cytoskeleton regulates connexin 43 localization and cardiac conduction in cardiomyopathy caused by mutation in A-type lamins gene. *Hum Mol Genet* (2018).
49. Gundersen, G.G. & Worman, H.J. Nuclear positioning. *Cell* **152**, 1376-1389 (2013).
50. Jung, H.J. *et al.* Regulation of prelamin A but not lamin C by miR-9, a brain-specific microRNA. *Proc Natl Acad Sci U S A* **109**, E423-431 (2012).
51. Coffinier, C. *et al.* Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons. *Mol Biol Cell* **22**, 4683-4693 (2011).

ACKNOWLEDGEMENTS

The authors thank Colin Stewart for providing the *Lmna* KO and *Lmna* N195K mouse models, Edgar Gomes for help with the *in vitro* myocyte differentiation protocol, Alexandra Corbin for *in vivo* and *in vitro* protrusion and cGAS analysis and *in vivo* Hsp90 localization analysis, Rebecca Mount for optimization of single fiber isolation and subsequent analysis, Daniel Huang for quantification of the *Lmna* N195K skeletal muscle fiber cross-sectional areas, Francoise Vermeulen, Stephen Parry and Lynn Johnson from the Cornell Statistical Consulting Unit, and Katherine Strednak and the Cornell Center for Animal Resources and Education (CARE) for help in maintaining the *Lmna* mutant mice. Clinical data from *LMNA* individuals was provided by Katherine D. Mathews, M.D. (Vice Chair for Clinical Investigation, Director, Muscular Dystrophy Clinic, Director, Iowa Neuromuscular Program, Professor of Pediatrics – Neurology and Professor of Neurology). Technical assistance with human muscle immunohistochemistry was provided by Nicholas M. Shaw and Margaret R. Ketterer (U. Iowa). This work was supported by awards from the National Institutes of Health (R01 HL082792 and U54 CA210184 to J.L.), the Department of Defense Breast Cancer Research Program (Breakthrough Award BC150580 to J.L.), the National Science Foundation (CAREER Award CBET-1254846 and MCB-1715606 to J.L.), the Muscular Dystrophy Association (Development Award MDA603238 to T.J.K.; 477283 to L.L.W.), a Fleming Postdoctoral Fellowship to T.J.K, National Science Foundation Graduate Research Fellowships (2013160437 to A.J.E.; 2014163403 to G.R.F.), Burroughs Wellcome Fund Collaborative Research Travel Grant (1017502 to L.L.W.), the University of Iowa Wellstone Muscular Dystrophy Cooperative Research Center (U54, NS053672 to S.A.M), and generous gifts from the Mills family to J.L. This work was performed in part at the Cornell NanoScale Science & Technology Facility (CNF), a member of the National Nanotechnology Coordinated Infrastructure (NNCI), supported by the National Science Foundation (Grant NNCI-1542081).

AUTHOR CONTRIBUTIONS

A.E., T.K., G.F., P.I., L.W., and J.L. contributed to the conception and design of the work; A.E., T.K., G.F., P.I., J.P., S.I., S.M. contributed to data acquisition and analysis; A.E., T.K., G.F., L.W., G.B., J.L. contributed to the interpretation of data; A.E., T.K., G.F., L.W., J.L. contributed to drafting the manuscript. All authors contributed to editing the manuscript.

COMPETING FINANCIAL INTERESTS

Nothing to declare.

DATA AND CODE AVAILABILITY

The data supporting the findings of this study are available from the corresponding authors upon reasonable request. MATLAB codes used for the microharpoon assay and micropipette aspiration analysis are available upon request.

METHODS

Animals. *Lmna* KO (*Lmna*^{-/-})⁹, *Lmna* N195K (*Lmna*^{N195K/N195K})¹⁰, and *Lmna* H222P (*Lmna*^{H222P/H222P})¹¹ have been described previously. *Lmna*^{+/-}, *Lmna*^{H222P/+}, and *Lmna*^{N195K/+} mice were backcrossed at least seven generations into a C57-BL/6 line. For each mouse model, heterozygous mice were crossed to obtain homozygous mutants, heterozygous mice, and wild-type littermates. *Lmna* mutant mice were provided with gel diet (Nutri-Gel Diet, BioServe) supplement to improve hydration and metabolism upon onset of phenotypic decline. *Dmd*^{mdx} mice have been described previously⁵²; mice were obtained from the Jackson Laboratory in a C57BL background and hemi- or homozygous animals were bred to produce all hemi- and homozygous offspring. Data from wild-type littermate controls for *Lmna* KO, *Lmna* N195K and *Lmna* H222P showed no differences in experimental outcomes amongst them; therefore, data from wild-type littermates was combined into a single group, unless otherwise specified. For both *in vivo* and *in vitro* studies, cells and or tissues were isolated from a single mouse and counted as a single replicate. All data are based on at least two independently derived primary cell lines for each genotype. All experiments, including breeding, maintenance, and euthanasia of animals, were performed in accordance with relevant guidelines and ethical regulations approved by the Cornell University Institutional Animal Care and Use Committee (IACUC), protocols 2011-0099 and 2012-0115.

NE rupture reporter mouse (cGAS/MB21D1-tdTom transgenic mouse). To detect NE ruptures *in vivo*, we generated a transgenic mouse expressing FLAG tagged human cGAS^{E225A/D227A} fused to a tdTomato fluorescent protein (cGAS-tdTomato) under the control of the commonly used constitutive active CMV promoter. The cGAS mutations are in the magnesium-binding domain, abolishing the enzymatic activity and downstream production of interferon, while still retaining the ability to bind to genomic DNA. The mammalian expression cassette including promoter and terminator (CMV-3xFLAG-cGAS^{E225A/D227A}-tdTomato-SV40polyA) was released from the expression vector, removing the prokaryotic domains. The purified linear DNA was then injected into the pronucleus of fertilized embryos collected from super-ovulated C57BL/6 mice and transplanted into pseudo-pregnant recipients. The resulting transgenic mouse model was used to cross into the *Lmna* KO background to generate 3xFLAG-cGAS^{E225A/D227A}-tdTomato positive *Lmna* KO mice within two generations.

Myoblast isolation. Cells were harvested from *Lmna* KO, *Lmna* N195K, *Lmna* H222P, and wild-type littermates between 3-5 weeks for *Lmna* KO mice, 4-6 weeks for *Lmna* N195K, and 4-10 weeks for *Lmna* H222P mice using a protocol adapted from⁹. With the exception of the *Lmna* KO myoblasts, these time-points were prior to the onset of disease phenotypes. Myoblasts from wild-type littermates were harvested at the same time. Muscles of the lower hindlimb were isolated, cleaned of fat, nerve and excess fascia, and kept in HBSS on ice until all mice were harvested. The muscles were digested in 4 ml:1 g of tissue wet weight in a solution of 0.5% Collagenase II (Worthington Biochemicals), 1.2 U/ml Dispase (Worthington Biochemicals), 1.25 mM CaCl₂ (Sigma) in HBSS/25 mM HEPES buffer. Digestion was carried out in a 37°C water bath for a total time of 60 minutes. At 20 minutes intervals, digestion cocktails were removed and triturated 40 times with a 5 ml pipet. In the case of difficult to digest tissues, an extra 25% of 1% Collagenase II was added to the digestion after 40 minutes.

When tissues were fully digested, the reaction was quenched using equal volumes of DMEM supplemented with 10% fetal bovine serum (FBS) and 1% P/S (D10 media, Gibco). The cell suspension was strained through 70 and 40 µm filters (Greiner Bioscience) sequentially to remove undigested myotube fragments and tendon. The cell suspension was centrifuged at 800 × g for 5

minutes and washed with 8 ml of D10 media for a total of four times. Cells were then resuspended in primary myoblast growth media (PMGM; Hams F-10 (Gibco) supplemented with 20% horse serum and 1% penicillin/streptomycin and 1 μ l/ml basic fibroblast growth factor (GoldBio)) and plated onto a 2% gelatin coated T25 flask. Cells were allowed to sit undisturbed for 72 hours. Capitalizing on the fact that myoblasts adhere much more weakly than fibroblasts, cells were passaged using PBS (calcium- and magnesium-free) instead of trypsin to purify the myoblasts. Cells were washed for 2-3 minutes at room temperature using a volume of PBS sufficient to coat the bottom of the flask and dislodged using manual agitation. When necessary, a 0.000625% trypsin solution was used to aid in the myoblast removal. Myoblasts were re-suspended in PMGM and re-plated onto gelatin coated flasks. This process was continued 3-4 times until pure myoblast cultures were achieved. Cells were maintained in culture on gelatin coated flasks with the media changed every other day. All experiments were carried out prior to passage 12. Each independent experiment was done on a different set of lamin mutant and wild-type littermates such that each independent experiment was sourced from a different animal to account for heterogeneity in phenotype.

Myoblast differentiation. Myoblasts were differentiated by modifying a published protocol⁷. Coverslips for differentiation were prepared by coating with CellTak (Corning) according to the manufacturer's protocol and then coating with growth factor reduced Matrigel (Corning) diluted 1:100 with IMDM with Glutamax (Gibco). Pre-cooled pipette tips were used to avoid premature polymerization. Matrigel was allowed to polymerize at 37°C for 1 hour and the excess solution was aspirated. Primary myoblasts were seeded at a density of 55,000 cells/cm² in PMGM. Cells were allowed to attach for 24 hours before being switched to primary myoblast differentiation media (PMDM) composed of IMDM with Glutamax and 2% horse serum without antibiotics. This timepoint was considered day 0. One day after the onset of differentiation, a top coat of 1:3 Matrigel:IMDM was added to the cells and allowed to incubate for 1 hour at 37°C. PMDM supplemented with 100 ng/ml agrin (R&D Systems) was added to the cells and henceforth replaced every second day. Cells were allowed to differentiate for a total of 0, 5, or 10 days.

Plasmids and generation of fluorescently labeled cell lines. Each of the mutant myoblast lines were stably modified with lentiviral vectors to express the nuclear rupture reporter NLS-GFP (pCDH-CMV-NLS-copGFP-EF1-blastiS) and cGAS-mCherry (pCDH-CMV-cGAS^{E225A/D227A}-mCherry2-EF1-blastiS). cGAS, a cytosolic DNA binding protein possessed the E225A/D227A amino acid substitutions that abolish enzyme activity and interferon production, but still bind DNA and serve as a NE rupture reporter¹⁶. For rescue experiments, *Lmna* KO cells were modified with human lamin A (pCDH-CMV-preLamin A-IRES-GFP-puro). To generate the DN-KASH and DN-KASHext constructs, GFP-KASH2 and GFP-KASH2ext were subcloned from previously published plasmids²⁸ and inserted into an all-in-one doxycycline inducible backbone (pPB-tetO-GFP-KASH2-EIF1 α -rtTA-IRES-Neo)⁵³. Plasmids are available from Addgene at https://www.addgene.org/Jan_Lammerding/

Viral and Piggybac modification. Pseudoviral particles were produced as described previously¹⁶. In brief, 293-TN cells (System Biosciences, SBI) were co-transfected with the lentiviral-containing, packaging and envelope plasmids using PureFection (SBI), following manufactures protocol. Lentivirus-containing supernatants were collected at 48 hours and 72 hours after transfection, and filtered through a 0.45 μ m filter. Cells to be transduced were seeded into 6-well plates so that they reached 50-60% confluency on the day of infection and transduced at most 2 consecutive days with the viral supernatant using the TransDux Max system (SBI). The viral

solution was replaced with fresh culture medium, and cells were cultured for 72 hours before selection with 1 $\mu\text{g}/\text{mL}$ of puromycin or 2 $\mu\text{g}/\text{mL}$ blasticidin S for 2-5 days. After selection, cells were subcultured and maintained in their recommended medium without the continued use of selection agents. For PiggyBac modifications, myoblasts were transfected with 1.75 μg of the PiggyBac plasmid and 0.75 μg of a Hyperactive Transposase using the Lipofectamine 3000 reagent according to the manufacture's guidelines.

Extended imaging using incubator microscope. Long term imaging was performed using an Incucyte imaging system, which allows for incubator imaging to minimize changes in humidity and CO_2 . The differentiating cells expressing combinations of NLS-GFP and cGAS-mCherry were imaged using the Incucyte dual color filter module from day 0 to day 10, every 30-60 minutes with a 20 $\times$ objective. Resulting images were analyzed using the Incucyte software, which performs fluorescence background subtraction using a Top-hat method and subsequent thresholding. cGAS-mCherry cells were thresholded and then analyzed for increase in fluorescent foci over time to track the rate of increase in NE rupture or damage. NLS-GFP cells were used to investigate the frequency and presence of NE rupture. To verify the results obtained from the Incucyte, cells were fixed and stained with appropriate antibodies to evaluate DNA damage and NE rupture.

Isolation of single muscle fibers. Single muscle fibers were harvested using a protocol adapted from Vogler et al.⁵⁴. Fibers were isolated from the hindlimb muscles of male and female *Lmna* KO and wild-type littermates at 5-6 weeks of age and *Lmna* N195K and wild-type littermates at 6-8 weeks of age. To compare pre- and post-phenotype onset, *Lmna* H222P and wild-type litter mates were harvested at 6-8 weeks of age and 23-25 weeks of age, respectively. Briefly, the extensor digitorum longus (EDL) and plantaris were isolated from the mouse and placed directly into a 1 ml solution of F10 media with 4,000 U/ml of Collagenase I (Worthington Biochemicals). The tissue was digested for 15-40 minutes depending on muscle size in a 37°C water bath with agitation by inversion every 10 minutes. The reaction was quenched by transferring the digestion mixture to 4 ml of PMGM. Single fibers were hand-picked from the digested tissue using fire polished glass Pasteur pipettes coated with FBS. When necessary, the tissue was further dissociated by manual pipetting with a large-bore glass pipet. Fibers were washed once in fresh media prior to fixation with 4% paraformaldehyde (PFA) for 15 minutes at room temperature and then stained.

Pharmacological treatments. Myoblasts were differentiated using the standard protocol and treated with pharmacological treatments starting at day 5 of differentiation. For chromatin protrusion studies, paclitaxel was administered to differentiated myotubes in two 24-hour bursts at day 4 and day 6-post differentiation with a 24-hour recovery in between. Myotubes were then fixed in 4% PFA at day 7 and stained with anti-lamin B and DAPI in order to quantify the percentage of myonuclei with chromatin protrusions. For long term studies using the cGAS reporter, myotubes were treated with 10 nM of paclitaxel starting at day 5 and media was refreshed every day. To inhibit myotube contraction, cells were treated with 5 μM nifedipine starting on day 5 and media was refreshed every day. For DNA damage induction and inhibitor experiments, cells were treated with 20 $\mu\text{g}/\text{ml}$ of phleomycin for a two-hour pulse on day 3, 4, and 5 of differentiation. Concurrently, cells were treated with NU7441 (2 μM), KU55933 (2 μM) starting on day 2 through 10 of differentiation. For induction of DN-KASH2 and DN-KASH2ext, cells were treated with 1 μM doxycycline.

Biophysical assays. To evaluate nuclear deformability in high throughput, we designed and fabricated a microfluidic, micropipette aspiration device¹². The mask and wafers were produced in the Cornell NanoScale Science and Technology Facility (CNF) using standard lithography

techniques. PDMS molds of the devices were cast using Sylgard 184 (Dow Corning) and mounted on coverslips using a plasma cleaner as described previously¹⁶. Three port entrances were made using a 1.2 mm biopsy punch. Pressures at the inlet and outlet ports were set to 1.0 and 0.2 psi (relative to atmospheric pressure, P_{atm}), respectively, using compressed air regulated by a MCFS-EZ pressure controller (Fluigent) to drive single cells through the device. Myoblasts ($\sim 5 \times 10^6$ cells/mL suspended in 2 % bovine serum albumin (BSA), 0.2 % FBS and 10 $\mu\text{g/mL}$ Hoechst 33342 DNA stain in PBS) were captured within an array of 18 pockets, and then forced to deform into 3 μm wide $\times$ 5 μm tall micropipettes. The selected pressures resulted in detectable nuclear deformations without causing significant damage to the cells (as evidence by lack of propidium iodide staining). The remaining port was set to P_{atm} and outfitted with a handheld pipette to flush cells from the pockets at the start of each image acquisition sequence. Brightfield and fluorescence images were acquired every 5 seconds for a minimum of 60 seconds using an inverted microscope and 20 $\times$ /NA 0.8 air objective. Nuclear protrusion length was calculated using a custom-written MATLAB program, made available upon request.

For perinuclear force application ('microharpoon assay'), myoblasts were seeded in 35 mm glass bottom dishes and differentiated as previously described, except without the addition of a Matrigel top coat that allowed for access with a microneedle ('microharpoon'). A Sutter P-97 micropipette puller was used to create microneedles from borosilicate glass rods (Sutter; OD: 1.0 mm, ID: 0.78, 10 cm length) with tip diameters of $\approx 1 \mu\text{m}$. Day 4 myotubes (*Lmna* KO and wild-type) were treated for 24 hours with either 50 nM Paclitaxel or the corresponding 0.1% DMSO. The following day, "microharpoon assays" were performed as previously described^{8, 13}, with slight modifications to the pull parameters to accommodate myotubes. The microharpoon was inserted $\approx 5\text{--}7 \mu\text{m}$ from the edge of the nucleus and pulled 15 μm at a rate of 1 $\mu\text{m/s}$. Pull direction was always along the long axis of the myofiber. Images were acquired at 40 $\times$ (+1.6 $\times$) every 5 seconds. Nuclear strain and centroid displacement were calculated using a custom-written MATLAB program, made available upon request.

siRNA treatment. siRNAs used were as follows: Kif5b#3 (target sequence 5'-CAGCAAGAAGTAGACCGGATA-3'; Qiagen SI00176050), Kif5b#4 (target sequence 5'-CACGAGCTCACGGTTATGCAA-3'; Qiagen SI00176057), and non-target (NT) negative control (ON-TARGETplus non-targeting pool, Dharmachon, D-001810-10). Myoblasts were seeded at a density of $\sim 15,000$ cells per well in a 96-well glass bottomed dish containing a matrigel coating. Once adhered, the myoblasts were transfected twice, 48 hours apart, with siRNA for NT or Kif5b using Lipofectamine RNAiMAX at a concentration of 150 nM in PMGM. After 12 hours, the myoblasts were switched to PMDM and differentiated for 5 days.

Immunofluorescence staining of mouse cells and tissues. Cells were fixed in pre-warmed 4% PFA at the appropriate time point(s) and washed with PBS. Cells were blocked and permeabilized with a solution of 3% BSA, 0.1% Triton-X 100 and 0.1% Tween (Sigma) for 1 hour at room temperature. Cells were stained with primary antibodies diluted in blocking solution according to Supplementary Table 2 at 4 $^{\circ}\text{C}$ overnight. Samples were washed with PBS and incubated for 1 hour at room temperature with 1:250 dilution of AlexaFluor antibodies (Invitrogen) and 1:1000 DAPI (Sigma). Single muscle fibers were stained using the same procedure in Eppendorf tube baskets with an increase in blocking solution Triton-X concentration to 0.25%.

Human patient biopsy staining. Following diagnostic testing, muscle biopsies were stored at -80 $^{\circ}\text{C}$ and subsequently utilized for research following protocols approved by the corresponding Internal Review Board (IRB), with informed consent from all participants. Cryopreserved human

quadricep muscle biopsy tissue from *LMNA* muscular dystrophy individuals and age-matched controls were used for immunostaining as described previously⁵⁵. An anti-rabbit polyclonal 53BP1 antibody (Novus) and anti-dystrophin mouse monoclonal antibody (Mab7A10, U of Iowa Hospitals and Clinics Pathology Core) were used at 1:1000 and 1:20 dilutions, respectively. Texas Red labeled phalloidin (Invitrogen) was used at 1:400 dilution. Secondary antibodies were a goat anti-rabbit Ig Alexa 488 conjugate (Invitrogen) and a goat anti-mouse IgG rhodamine Red-X conjugated (Molecular Probes), both used at 1:500 dilution. Slides were imaged on a Zeiss 710 confocal microscope (University of Iowa Central Microscopy Facility). The intensity of nuclear anti-53BP1 staining was quantified using ImageJ. Analysis of the human muscle samples was performed in a double-blinded manner. A pathologist generated the 10 μ m thick cryo-sections and coded the samples, which were stained, imaged, and quantified prior to decoding by an independent researcher. The human muscle biopsy tissues were collected, processed, and analyzed according to all ethical regulations. The use of the human tissues for research purposes was approved by the University of Iowa Human Subjects Office IRB, protocol #200510769. All tissues used in this study were de-identified.

Western analysis. Cells were lysed in RIPA buffer containing protease (cOmplete EDTA-Free, Roche) and phosphatase (PhosSTOP, Roche) inhibitors. Protein was quantified using Bio-Rad Protein Assay Dye and 25-30 μ g of protein lysate was separated using a 4-12% Bis-Tris polyacrylamide gel using standard SDS-Page protocol. Protein was transferred to a polyvinylidene fluoride (PVDF) membrane overnight at 4°C at a current of 40 mA. Membranes were blocked using 3% BSA in tris-buffered saline containing 0.1% Tween-20 and primary antibodies (Supplementary Table 2) were diluted in the same blocking solution and incubated overnight at 4°C. Protein bands were detected using either IRDye 680LT or IRDye 800CW (LI-COR) secondary antibodies, imaged on an Odyssey® CLx imaging system (LI-COR) and analyzed in Image Studio Lite (LI-COR)

Imaging acquisition. Cells on coverslips and mounted single muscle fibers were imaged with an inverted Zeiss LSM700 confocal microscope. Z-stack were collected using 20 $\times$ air (NA = 0.8), 40 $\times$ water-immersion (NA = 1.2) and 63 $\times$ oil-immersion (NA = 1.4) objectives. Airy units for all images were set between 1 and 1.5. Epi-fluorescence images were collected on a motorized inverted Zeiss Observer Z1 microscope equipped with CCD cameras (Photometrics CoolSNAP EZ or Photometrics CoolSNAP KINO) or a sCMOS camera (Hamamatsu Flash 4.0). H&E histology images were collected on an inverted Zeiss Observer Z1 microscope equipped with a color CCD camera (Edmund Optics, EO-0312C).

Image analysis. Image sequences were analyzed using ZEN (Zeiss), ImageJ, or MATLAB (Mathworks) using only linear adjustments uniformly applied to the entire image region. Region of interest intensities were extracted using ZEN or ImageJ. To quantify cleaved caspase-3 (i.e. active) area and myofiber health, maximum intensity projections were generated, which were then blinded to the observer. Cleaved caspase-3 area was calculated by thresholding of the caspase-3 and myosin heavy chain fluorescent signal and expressing the cleaved caspase-3 signal relative to the myosin heavy chain signal. Myofiber contractions were scored using a blinded analysis according to the scales provided in Extended Data Figure 1a. To count the number of DNA protrusions, and DNA damage foci, confocal image stacks were three-dimensionally reconstructed and displayed as maximum intensity projections. Protrusions lengths were both counted and measured by the presence of DAPI signal beyond the lamin B rim of the nucleus. Aspect ratio was quantified based on a thresholded lamin B rim to avoid the confounding factor of the DNA

protrusions outside the body of the nucleus. Nuclear rupture was detected by an increase of the cytoplasmic NLS-GFP signal, or the localization of cGAS-mCherry to the nucleus. For better visualization of NLS-GFP cells many of the fluorescent single color image sequences were inverted. Graphs were generated in Excel (Microsoft), and figures were assembled in Illustrator (Adobe). DNA damage was determined by counting H2AX foci and then binned based on foci number. If damage was so severe that individual foci could not be counted, these nuclei were placed in the >25 foci category. For Hsp90 quantification, average nuclear Hsp90 fluorescence intensity was determined from a single mid-nucleus z-plane image and normalized to the cytoplasmic intensity at two points immediately adjacent to the nucleus.

MTT assay. Myoblasts, seeded in a 96-well plate and differentiated as previously described for 0, 5, or 10 days, were assayed for cell viability according to the manufacturer's instructions (Promega, CellTiter 96 Non-Radioactive Cell Proliferation Assay). Fresh differentiation media was added two hours prior to the addition of 15 μ L MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye. After incubation for 3 hours in MTT dye, 100 μ L of Stop Solution was added to solubilize the formazan product (appears purple). Following overnight incubation at 37°C and 5% CO₂, the absorbance of each well (measured at 590 nm) was analyzed using a microplate reader.

Gamma irradiation. A pulse of gamma-irradiation (5 Gy) was administered to myotubes differentiating (5 days) in a 96 well plate. Non-irradiated controls, along with treated cells following 3, 6, or 24 hours of recovery, were PFA-fixed and stained with anti- γ H2AX, anti-lamin B and DAPI. A custom macro was used to quantify the mean integrated density of nuclear γ H2AX signal from maximum intensity projections of confocal z-stacks.

Statistical analysis. Unless otherwise noted, all experimental results were taken from at least three independent experiments and *in vivo* data were taken from at least three animals. For data with normal distribution, we used either student's t-tests (comparing two groups) or one-way ANOVA (for experiments with more than two groups) with post-hoc tests. When multiple comparisons were made, we adjusted the significance level using Bonferroni corrections. All tests were performed using GraphPad Prism. Micropipette aspiration data were natural log-transformed (Supplementary Figure 3) and analyzed by linear regression of the log-log data. In addition, data was analyzed with a multilevel model, in which the log-transformed protrusion length was the dependent variable in the model and the log-transformed time, genotype, and their interaction were treated as independent fixed effects. Variance from individual experiments and other effects were considered in the model as random effects. Post-hoc multiple comparisons test with Dunnett correction were performed to determine differences between *Lmna* mutant cells (*Lmna* KO, *Lmna* N195K, and *Lmna* H222P) and control cells (pooled wild-type). Analyses were carried out using JMP software. For human tissue samples, the intensity values did not meet the criteria for a normal distribution. Therefore, a two-sided Kruskal-Wallis one-way analysis of variance (ANOVA), followed by the two-sided Dunn post hoc test were used to determine if there was a significant difference in staining among the genotypes. For comparisons that involved one sample and one age-matched control, a two-sided Mann-Whitney non-parametric test was performed. Unless otherwise indicated, error bars represent the standard error of the mean (SEM). Data supporting the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES:

52. Bulfield, G., Siller, W.G., Wight, P.A. & Moore, K.J. X chromosome-linked muscular dystrophy (mdx) in the mouse. *Proc Natl Acad Sci U S A* **81**, 1189-1192 (1984).
53. Shurer, C.R. *et al.* Physical Principles of Membrane Shape Regulation by the Glycocalyx. *Cell* **177**, 1757-1770 e1721 (2019).
54. Vogler, T.O., Gadek, K.E., Cadwallader, A.B., Elston, T.L. & Olwin, B.B. Isolation, Culture, Functional Assays, and Immunofluorescence of Myofiber-Associated Satellite Cells. *Methods in molecular biology* **1460**, 141-162 (2016).
55. Dialynas, G. *et al.* Myopathic lamin mutations cause reductive stress and activate the nrf2/keap-1 pathway. *PLoS Genet* **11**, e1005231 (2015).








Fig. 1

Fig. 2**a****b****c****d****e****f**

Lamin B1/Myosin heavy chain


g









Fig. 3**a****b****c****d****e****f****g****h**


Fig. 4


Fig. 5

Fig. 6